CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement Post author:GHIAA Admin Post published:May 24, 2022 Post category: Continue ReadingCSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement Post author:GHIAA Admin Post published:April 26, 2022 Post category: Continue ReadingBMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
Cellscript – BioNTech mRNA Technology Patent Sublicense Post author:GHIAA Admin Post published:March 17, 2022 Post category: Continue ReadingCellscript – BioNTech mRNA Technology Patent Sublicense
Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement Post author:GHIAA Admin Post published:March 4, 2022 Post category: Continue ReadingBiological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
CEPI – Novavax, COVID-19 Vaccine Funding Agreement Post author:GHIAA Admin Post published:February 28, 2022 Post category: Continue ReadingCEPI – Novavax, COVID-19 Vaccine Funding Agreement
Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement Post author:GHIAA Admin Post published:February 2, 2022 Post category: Continue ReadingGavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
CEPI – Dynavax, COVID-19 Material Reservation Agreement Post author:GHIAA Admin Post published:January 31, 2022 Post category: Continue ReadingCEPI – Dynavax, COVID-19 Material Reservation Agreement
Academic Institution – Company, Research Collaboration Agreement Post author:GHIAA Admin Post published:January 12, 2022 Post category: Continue ReadingAcademic Institution – Company, Research Collaboration Agreement
University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement Post author:GHIAA Admin Post published:January 11, 2022 Post category: Continue ReadingUniversity of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement